Riber reports 19% yoy H1 2026 revenue growth, returns to profitability amid ROSIE platform expansion. 2026-09-29 10:16:49 Riber posts 19% year-over-year first-half 2026 revenue growth to €12.7M. France-based Bezons firm Riber, a leading maker of molecular beam epitaxy (MBE) systems, has announced a 19% year-over-year rise in first-half 2026 revenue, climbing from €10.7m in H1 2025 to €12.7m this year. The strong performance is fueled by explosive growth in its Services & Accessories division and steady Systems sales. Revenue from Services & Accessories jumped 71% over the same period last year, rising from €3m to €5.1m. Systems revenue held nearly flat year-over-year at €7.7m, compared to €7.8m in H1 2025, with three units delivered in both six-month periods. Revenue growth lifts Riber back to profitability. The company's gross margin also saw a healthy uptick, moving from 36.2% in H1 2025 to 39.8% in H1 2026. Combined with careful control of operating expenses, this margin growth and higher top-line revenue pushed Riber back into net profit: the firm reported a net income of €0.2m for H1 2026, a €1m improvement from its €0.8m net loss in the first half of 2025. This result includes €0.1m in net financial income. As of the end of June 2026, Riber held €5.2m in cash, up from €2.5m at the end of June 2025, though lower than the €7.5m cash position it reported at the end of December 2025. Shareholders' equity dropped slightly from €27.3m at the end of 2025 to €25.7m at mid-2026, primarily due to a €2.1m payout to shareholders from the issue premium account in June. Financial debt (excluding IFRS 16 standards) reached €6.4m as of June 2026, up from €1.4m at the end of 2025 and €2.3m at mid-2025. This figure includes €6m in bank loans Riber secured in the first half of 2026 from Bpifrance and top French banking institutions. As a result, Riber held net debt of €1.2m at mid-2026, compared to net cash of €0.2m at the same point last year. Bank financing drives continued development of the ROSIE epitaxy platform. With the €6m in bank funding secured, Riber is moving forward with its long-term strategic roadmap. The ROSIE (RIBER Oxide Silicon Epitaxy) platform is built to grow functional oxides on 300mm silicon wafers, fully compliant with SEMI global industry standards. The technology is designed for integrated silicon photonics use cases, including electro-optical parts for telecom networks, data centers, and select quantum computing architectures. The second ROSIE system was shipped in July to a leading quantum computing company based in the United States. Riber is now speeding up the industrialization of ROSIE II, a dual-chamber cluster production platform that is the next iteration of the ROSIE line. "With support from our financial partners, we are hitting a key milestone as we advance the buildout of ROSIE II. This new platform will let us speed up process qualification and get the technology ready for full commercial launch," shared Riber Chair and CEO Annie Geoffroy. The ROSIE II system will help mature the platform's technology, speed up qualification of BTO/STO (barium titanate oxide/strontium titanate oxide) production processes under real industrial operating conditions, and pave the way for wide commercial rollout. Riber notes it may use the first completed ROSIE II unit to manufacture technology wafers, or assign it to an industrial partner customer. The first BTO/STO samples developed as part of Riber's partnership with the Novo Nordisk Foundation Quantum Computing Programme (NQCP) will be available to customers in the fourth quarter of 2026. Multiple laboratories and industrial firms have already confirmed interest in the technology, with pre-orders placed for the specialized wafers. Riber has also been invited to join major new industrial and technology partnerships to support the creation of new use cases for its tech. "We keep expanding our product portfolio by combining epitaxy and deposition technologies, plus building out process automation solutions," Geoffroy added. "We are staying on track with our roadmap, with goals to strengthen our offerings built on our established core technologies, and tap into new opportunities in photonics, quantum technologies, and advanced deposition solutions." Mid-2026 order book remains strong despite headwinds. Riber reports that its commercial activity continues to hold up well, especially for use cases related to datacom and quantum technologies. As of the end of June 2026, the company's total order book stood at €26.8m, a 3% dip from the €27.7m recorded at mid-2025. The drop is attributed to export restrictions to Asia that blocked more than €8m in potential orders, plus longer purchase decision timelines from some customers. Systems orders fell 27% year-over-year from €22.5m to €16.5m, covering four total units: three production systems and one ROSIE platform. This figure does not include a July 9, 2026 announced order for a production system from a European customer, which is scheduled for delivery in 2027. In contrast, Services & Accessories orders nearly doubled year-over-year, jumping from €5.2m to €10.3m. This growth was driven by spare part sales for recently shipped equipment, plus multiple upgrade projects for long-time Riber customers in North America. "Our first half 2026 results prove the strength of our core business, even as we operate in a complex global market," said Geoffroy. "The strong growth in our Services & Accessories division, plus ongoing high interest in our core technologies, are very positive signs for our future." Full-Year 2026 business outlook. Riber notes that its sales are historically seasonal, with most unit deliveries falling in the second half of the year, so first-half results cannot be used to predict full-year performance directly. The company says its target markets continue to see positive long-term growth trends, especially in photonics, artificial intelligence, and quantum technology segments. It also expects sustained high demand for its Services & Accessories offerings. If Riber secures the required export licenses for Asian markets, it expects full-year 2026 revenue to be roughly on par with 2025 full-year results. Governance update. During a September 22, 2026 board meeting, Riber's board of directors accepted the resignation of independent director Nicolas Grandjean, who stepped down for professional reasons. The board thanked Grandjean for his contributions to the company and his commitment during his term in office.

Historic agreement with Novo Nordisk Foundation strengthens Nordic research co-operation. The Novo Nordisk Foundation (NNF) and NordForsk have signed a framework agreement to fund Nordic research co-operation over the period 2026-2030. The agreement will strengthen the scope of open, competitive calls across the Nordic region. During the first part of the agreement period, NNF will contribute up to 50 million Danish kroner to NordForsk's calls, with the possibility of additional contributions later in the period. "This is a historic agreement. It is the first time that a private research foundation has entered into a binding collaboration of this kind with an institution under the Nordic Council of Ministers. The agreement will contribute to a significant strengthening of Nordic research co-operation and enable us to ensure that even more excellent research is carried out in the Nordic region," says Johnny Mogensen, Director of NordForsk. "For us at the Novo Nordisk Foundation, it is a core priority to strengthen Nordic collaboration in research and innovation. NordForsk is a unique institution in this regard, as it provides access to open calls across the Nordic countries," says Søren Nedergaard, Chief Portfolio Officer at the Novo Nordisk Foundation. Strengthening the Nordic Region's position as a leading research area. Karen Ellemann, Secretary General of the Nordic Council of Ministers, sees the agreement as an example of how Nordic research co-operation can bring together efforts across sectors and countries. "The societal challenges we face today cannot be solved by any single actor alone. This agreement is an important step towards strengthening collaboration between the public and private sectors. Together, we can give research projects greater momentum, strengthen the Nordic region's position as a leading research area, and bring us closer to the vision of becoming the world's most sustainable and integrated region," says Ellemann. The purpose of the agreement is to ensure clarity and transparency in future collaborations on calls and research projects. Funding from NNF may be used for co-financing in the fields of health, sustainability and life sciences. Both parties emphasise that these funds are intended to complement, not replace, contributions from national funding sources. The agreement covers the period 2026-2030. NordForsk will be responsible for calls, project follow-up and administration, while a joint management-level contact committee will be established to meet annually and prioritise and monitor the collaboration.